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Abstract
The alternatively spliced type-III extradomain B (EIIIB) of Fibronectin (FN) is only expressed during
embryogenesis, wound healing and tumorigenesis. The biological function of this domain remains
unclear. We describe here the first crystal structure of the interface between alternatively-spliced
domain EIIIB and its adjacent FN type-III domain 8 (FN B-8). The opened CC′ loop of EIIIB and
the rotation and tilt of EIIIB domain allows good access to the FG loop of FN-8 which is normally
hindered by the CC′ loop of FN-7. In addition, the AGEGIP sequence of the CC′ loop of EIIIB
replaces the NGQQGN sequence of the CC′ loop of FN-7. Finally, the CC” loop of EIIIB forms an
acidic groove with FN-8. These structural findings warrant future studies directed at identifying
potential binding partners for FN B-8 interface, linking EIIIB to skeletal and cartilagenous
development, wound healing, and tumorigenesis, respectively.
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Introduction
Fibronectin (FN) is a multifunctional protein serving major roles in the adhesion, migration,
differentiation and proliferation of cells with implications in embryonic development, wound
healing, and tumorigenesis.1 The significance of FN in embryonic development has been
documented by the embryonic lethality seen in mice when the FN gene is disrupted.2 FN is a
high molecular weight dimeric glycoprotein with disulfide-linked subunits, each with a
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molecular weight of approximately 220–250 kDa. FN interacts with several other proteins in
the ECM including collagen, heparin, fibrin, and cell membrane receptors. The amino acid
composition of FN reveals it to be a large modular glycoprotein composed of homologous
repeats of three prototypical types of domains known as types-I, II and III.3 Of these domains,
FN type-III (FN-III) repeats are composed of ≈ 90 amino acids making them the largest and
most common of the FN subdomains.4 One of the best characterized interactions between FN
and cell membrane receptors is the interaction between the RGD sequence of FN-III domain
10 (FN-10) and the extracellular domain of β1-integrin.5–7 This interaction is believed to
regulate integrin signaling and therefore may play an important role in integrin-mediated cell
differentiation.8–10
Among the type-III domains of FN that span the central part of FN molecule, three regions
referred to as EIIIA, EIIIB and IIICS respectively, are subject to alternative splicing of a
primary transcript.3–11 Of these spliced domains, EIIIA and EIIIB are either included or
excluded by exon skipping and their alternative splicing is regulated in a tissue-specific and
developmental stage-dependent manner.11–12 The amino acid sequence of alternatively
spliced exons EIIIA and EIIIB is well conserved, suggesting their functional importance.13
Initial studies showed EIIIA and EIIIB splice variants of FN prominently expressed around
developing blood vessels during embryonic development.14–15 These splice variants are
absent in normal adult tissues except during wound healing and neoplastic vascularization.
However, EIIIB- and EIIIA-null mice develop normally with only some small differences in
wound healing, atherosclerosis and life-span in the EIIIA null mice.13 Fibroblasts cultured
from EIIIB null mice grow slowly in vitro and deposit less FN in the pericellular matrix
compared to fibroblasts cultured from wild-type mice.12 EIIIB expression is predominantly
found in breast and colorectal carcinomas. It was believed that tumor cells express EIIIB FN
to recruit endothelial cells in order to supply the tumor mass with oxygen and nutrients. Thus,
EIIIB may be one of a few clinical markers of neovascularization.16 Antibodies and variations
of recombinant antibodies against EIIIB were proposed to be used in detections and treatments
of several tumors including oral and mammary carcinomas.17–18
The primary structure and electromicrographs suggested that FN-III is an extended molecule
composed of repeated sequence motifs described as “beads on a string”.19–20 The crystal
structure of FN type III domains 7 to 10 (FN7–10) that includes the RGD loop in domain 10
and the PHSRN synergy site in domain 9 has been previously published.4 The structure of FN-
EIIIB alone was also solved by NMR. 21 The individual FN type-III domains are very similar
to each other and each domain consists of two β strands, one of four strands (G, F, C and C′)
and one of three strands (A, B, and E).4 Each domain in FN-III has low sequence identity
(approximately 30% or lower), but they all have highly conserved secondary structural
frameworks.4,21 The major variable factor between each FN-III domain is the interdomain
interface which appears to be specific to each domain pair.4 Of interest, the interdomain buried
surface area between type-III domains 7 to 10 varies and the maximum buried surface area is
between domains 7 & 8.4 Similarly, the tilt between type-III domains 7–10 of FN also varies
with the maximum tilt (52 degrees) between domains 7 & 8. There is unfortunately no general
rule in the orientations between adjacent domains. EIIIB insertion between type-III domains
7 and 8 undoubtedly alters not only the interface, but possibly also the overall molecular
polarity as a consequence of domain flips. As a consequence of the insertion of EIIIB between
type-III domains 7 & 8, it was also hypothesized that these structural conformational changes
of fibronectin would alter its interactions with other proteins thereby modulating extracellular
signaling cascades in embryogenesis, wound healing, and neovascularization. To understand
the role of EIIIB insertion and the interface between FN type-III domain extra domain B (EIIIB)
and domain 8 (FN-8), we solved a 2.0 Å resolution crystal structure of FN-III fragment of
EIIIB and FN-8. The structure reveals a unique interdomain relationship and provides structural
insights into possible biological roles of EIIIB.
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The Overall Structure of FN-B8
We initially attempted to crystallize the recombinant fragment of FN-III domain 7 (FN-7),
EIIIB, and FN-8 (primary structure shown in Fig 1A). However, the crystals were too small
and failed to yield sufficient x-ray diffraction. Since the FN 7–10 structure is already
known4, we changed our strategy to make two shorter constructs-FN 7-B (FN-7 and EIIIB),
and FN B-8 (EIIIB and FN-8). FN 7-B grew very small needle-like crystals that failed to yield
sufficient x-ray diffraction. On the other hand, the FN B-8 fragment readily crystallized in 10–
15% (w/v) PEG-3350 and 0.15–0.2 mM diammonium citrate((NH4)2HC6H5O7)) and the
crystals diffracted well. The crystal structure of FN B-8 was determined by molecular
replacement of previously solved FN-8 (RSCB code 1fnf). The structure was refined to 2.01
Å (Table 1) with R=24.9% and Rfree=30.1% (Fig 1A–C). We were unable to completely trace
the N-terminal histidine tag and several amino acids thereafter. This highly flexible N-terminal
portion may contribute to slight increased of the R values. However, these refinement statistic
values are mimicking the ones of the 2.0 Å of the crystal structure of type III fibronectin solved
previously.4
FN B-8 appears to be a monomeric structure in one crystallographic asymmetric unit. Like
other crystal structures in the fibronectin family, the overall structure of FN B-8 is composed
of two copies of β sandwich globular domains (Fig 1B). Each β sandwich domain is formed
by an intimate anti-parallel embrace of three anti-parallel β-strands (A, B, and E) on one side,
and four anti-parallel β-strands (C′, C, F, and G) on the opposite side.
The general framework of the EIIIB is almost identical to the NMR structure of FN-B (RSCB
code: 2fnb; Fig 1D).21 However, the crystal structure showed clearly that the formation of
longer anti-paralleled β-strands compared to the NMR structure. The rmsd between the Cα
positions of our crystal structure and the NMR structure is as close as 2.5 Å. This allows us to
validate our phasing information since we did not use the NMR structure for our molecular
replacement. We believe that the molecular arrangement and packing of the crystal may
contribute tightly β strand to β strand relationship in our structure compared to the NMR one.
The overall fold of FN-8 is also similar to the previous crystal structure (rmsd =4.2 Å; Fig 1D).
The only obvious change in our FN-8 structure is the formation of extra β-G′ strand. While,
this alteration is possibly caused by crystal packing, it is clear that the additional extra domain
B has minimal effect on the overall structural arrangement of FN-8.
FN-B Structurally Alters Macromolecular Structure of Fibronectin
We further compared our EIIIB with the previously solved FN-7. As expected, the overall
frameworks of EIIIB and FN-7 are also very similar (rmsd=3.3 Å). The only noticeable
alteration in the structural framework is that the β-E strand of the EIIIB seems to be longer and
more structured than the one of FN-7 (Fig. 2A). While the general architectures of the EIIIB
and FN-7 are alike, the interactions between FN-7 and FN-8 are distinctively different from
the ones of EIIIB and FN-8.
When we superimposed FN-8 of our structure and FN-8 of 1fnf structure, we discovered three
distinctions between the FN-7/FN-8 and FN-B/FN-8 structures (Fig 2A). First, the bending
angle between EIIIB and FN-8 in our structure appears to be approximately 63° or about 11°
more than the angle between FN-7 and FN-8 (previously reported 52°).4 Secondly, the rotating
angle between EIIIB and FN-8 is approximately 117º or about 5º different from the one between
FN-7 and FN-8 (previously reported 112º).4 Finally and perhaps most importantly, the
locations and conformations of AB, CC′, and EF loops of FN-B are different from the ones of
FN-7.
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FN-B and FN-8 Interface
The location and conformation of EF loops are the most conserved among other loops in the
interface. The more acute bending of AB loop in domain B allows the dimer to bend further,
which coincides with the rotation of the domain B and the opening of CC′ loop. The interdomain
linker between EIIIB and FN-8 buries 416 Å2 of surface area, while the interdomain linker
between FN-7 and FN-8 buries 587 Å2 of surface area. The insertion of EIIIB clearly opens
up the buried surface over 170 Å2. The buried interface of EIIIB and FN-8 (416 Å2) is also
less than the one between FN-8 and FN-9 (527 Å2), but more than the one between FN-9 and
FN-10 (333 Å2). Therefore, the interface of EIIIB and FN-8 is the second smallest buried
interface among the known FN-III interdomain interfaces. The smallest FN-III buried interface
belonging to FN-9 and FN-10 is believed to allow the RGD sequence of FN-10 and the synergy
sequence (PHSRN) of FN-9 to function together in the interaction with integrin.4,7 This
alteration in the buried interface and the size of the FN B-8 interface suggest that it is possible
that the CC′ loop between the interface of EIIIB and FN-8 may behave akin the RGD of FN-10
and the synergy region of FN-9.
We further examined the electrostatic potential surface of FN B-8 (Fig 2B). The CC′ loop of
EIIIB forms an acidic groove with FN-8. In addition, The AGEGIP sequence of the CC′ loop
of EIIIB is distinct from the NGQQGN sequence of the CC′ loop of FN-7 (Fig 1A). An
equivalent acidic groove, forming by the CC′ loop and its adjacent domain, was also identified
in another FN-III-like structure, the FN-III domains of the cytoplasmic tail of integrin β4.22
The sizes of these two homologous acidic grooves are almost the same, approximately 20 ×
10 Å. The acidic groove and the CC′ loop were proposed to be potential protein-protein
interacting sites.22 We also found that the neighboring molecule in the crystal structure packs
in nicely into this acidic groove. The opened CC′ loop of EIIIB and the rotated and tilted of
EIIIB domain allow a good access to the FG loop of FN-8, which is normally hindered by the
CC′ loop of FN-7 (Fig 2A).
Defining the Potential Protein Binding Site
We have determined the high resolution crystal structure of the FN type III domains EIIIB and
8 and compared it with the known structure of FN type III domains 7 & 8. Of interest was the
buried interdomain interface between EIIIB and FN-8 and its comparison to the one of FN-7
and FN-8. Our crystal structure of FN B-8 shows that the interface between EIIIB and FN-8
is the second smallest of known FN-III structures and the CC′ loop of EIIIB forms a unique
acidic groove with the FN-8. The groove is large enough to allow the neighboring molecule in
the crystal to pack. In addition, the bending angle between EIIIB and FN-8 in our structure
appears to be tilted about 11º more than the angle between FN-7 and FN-8. The rotating angle
between EIIIB and FN-8 is also approximately 5° different from the one between FN-7 and
FN-8. Given the rotation angles between the various type-III domains of FN (7–10) and the
biologic significance attached to it (e.g., RGD and PHSRN loops in domains 10 and 9
respectively), it was speculated that insertion of EIIIB between domain 7 & 8 could alter the
downstream structure by causing the domains to be flipped. Our data suggest that insertion of
EIIIB may not have any downstream effects with respect to alteration of domain polarity.
Finally and perhaps most significantly, the locations and conformations of AB, CC′, and EF
loops of FN-B are different from the ones of FN-7.
Proposed Potential Protein Binding Site
Although the expression of spliced domain EIIIB is highly regulated during embryonic
development, wound healing and tumorigenesis, there is no well defined function for this
spliced domain of FN. Interestingly, even the EIIIB-null mice fail to reveal a clear function for
domain EIIIB although embryonic fibroblasts prepared from the EIIIB−/− mice showed slower
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proliferation and the FN fibrils assembled by these embryonic fibroblasts were shorter and
thinner compared to those deposited by the wild type fibroblasts.12 These findings suggest
that FN EIIIB may play a specific role in the regulation of particular matrix assembly and FN
matrix-dependent cell growth. It has been shown that EIIIB-containing FN produced by
cultured chondrocytes is preferentially incorporated in the cartilage matrix. EIIIB+ FN has also
been described in the walls of smaller blood vessels, smooth muscle of the gastro-intestinal
and respiratory tracts and cartilaginous structures.15
FN is known to utilize short-peptide surface loops in engaging its interactions with other
proteins in the signaling pathway, for example the RDG sequence of FN-10,6 the PHSRN
sequence of FN-9,23 and the KNEED sequence of FN-8.24 Based on our crystal structure, it
is tempting to speculate that the AGEGIP sequence of CC′ loop of EIIIB may be a potential
site for protein binding. However, there is no evidence at present that the AGEGIP is the protein
binding site and studies are in progress to further examine this potential binding site.
Preliminary analysis of cell lysates showed several proteins (data not shown) binding to FN 7-
EIIIB-8 and not FN 7–8 in a reproducible manner (affinity chromatography and 2D gel analysis
three times). Further characterization of binding proteins to the FN 7-EIIIB-8 is in progress.
Protein Data Bank accession number
The structural coordinate was deposited to the Protein Data Bank (RBSC code: 2GEE).
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Figure 1. Crystal structure of FN-B8
(A) The primary and secondary structures of type III fibronectin domain 7, B and 8 are shown
in green, black and magenta, respectively. The sequences of CC′ loops of FN-7, FN-B and
FN-8 are highlighted.
(B) A molscript diagram of FN B-8 structure. The β sandwiches are shown in yellow and red.
(C) 2.01 Å simulated annealing omit fofc electron density map contouring at 3.0σ. The map
was calculated via |Fobs| − |Fcalc|, ϕcalc, with these amino acids and a sphere 1.0 Å around
them omitted prior to annealing and map calculation. Part of β-C (residues 125–127), β-F
(residues 165–167) and β-G (residues 175–177) strands of EIII-B are shown here.
(D) Superimposition of our EIII-B structure with previously solved NMR structure (RSCB
code: 2fnb) demonstrates the similar overall folds.
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Figure 2. EIIIB alters the fibronectin structure
(A) Superimposition of EIIIB-8 of FN B-8 structure (shown in yellow/red) with FN 7–8
previously solved, RSBC code: 1fnf (shown in green), demonstrates that the differences in
torsion and bending angles of FN B-8 compared with the FN 7–8; and the conformational
differences of the AB, EF, and CC′ loops in EIIIB and FN-7. The two orientations are related
by a rotation of 180°.
(B) Molecular electrostatic potential surface representation of FN B-8 is colored by charge
distribution (red negative, white neutral and blue positive) using program Pymol (DeLano,
W.L., www.pymol.org).
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Table 1
Protein expression and crystallization
A recombinant fragment of human – type III fibronectin FN-B and FN-8 (FN-B8) was amplified by PCR and subcloned
into the pET15b expression vector. The protein was expressed and purified as previously described.4,25 FN-B8 was
concentrated to 6 mg ml−1 in 20 mM Tris pH 8.0, and crystallized using sitting drop vapor diffusion at 22°C. Crystals
of 200–300 μm in size grew in 10% (w/v) PEG-3350 and 0.15–0.2 mM diammonium citrate ((NH4)2HC6H5O7). The
crystals were cryo-protected in 30–40% (v/v) glycerol plus 60–70% (v/v) mother liquor prior to flash cooling in liquid
nitrogen.
Structure determination and refinement. Diffraction data were collected at the X-ray Facility at the University of
North Carolina-Chapel Hill. The experiments were performed at 100 K using cryo-cooled crystals, and were processed
and reduced using DENZO, SCALEPACK, and HKL2000.26 The FN-B8 structure was determined by molecular
replacement (AmoRe)27 using the structure of FN-8 (RBSC code: 1fn1)4 as a search model. Residues 87–274 (188
residues) of the 223 amino acids were traced. Structures were refined using torsion angle dynamics in CNS28 with the
maximum likelihood function target, and included an overall anisotropic B-factor and a bulk solvent correction. About
10 percent of the observed data were set aside for cross-validation using free-R prior to any refinement. Manual
adjustments were performed using the program O29 and σA- weighted30 electron density maps. Simulated annealing
omit and σA-weighted difference density maps were used. Final structures exhibit good geometry with no
Ramachandran outliers. Molecular graphic figures were created with MolScript,31 BobScript,32 Raster3D,33 and
Pymol (DeLano, W.L., www.pymol.org).
Resolution (Å; highest shell) 50-2.0 (2.13–2.01)
Space Group P212121





1 (%; highest shell) 8.2 (48.3)
Completeness (%; highest shell) 99.6 (98.5)
Mean I/σ (highest shell) 36.6 (6.0)
Rcryst
2 (%; highest shell) 24.9
Rfree
3 (%; highest shell) 30.1
Number Protein Atoms 1443
Number Solvent Sites 384
1
Rsym = ∑|I−<I>| / ∑I, where I is the observed intensity and <I> is the average intensity of multiple symmetry-related observations of that reflection.
2
Rcryst = ∑||Fobs|−|Fcalc|| / ∑Fobs|, where Fobs and Fcalc are the observed and calculated structure factors, respectively.
3
Rfree = ∑||Fobs|−|Fcalc|| / ∑Fobs| for 10% of the data not used at any stage of structural refinement.
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